Adam Cotton

Adam Cotton is a professional in the biotech investment sector, currently serving as a Board Observer at ONL Therapeutics and GentiBio, and as an Associate at Novartis Venture Fund where investments are made in early-stage biotech companies. Prior experience includes roles as an Analyst and Board Observer at various companies, including Hyku Biosciences and Mediar Therapeutics, and as a Co-Founder of EpiBiologics, focused on protein degradation platforms. Adam Cotton has also consulted at RA Capital Management, contributing to drug discovery initiatives, and was a PhD candidate at the University of California, San Francisco, specializing in antibody engineering and chemical synthesis. Educational credentials include a PhD in Chemistry and Chemical Biology from UCSF, an MBA in General Management from UNM Anderson, and an A.B in Chemistry from Harvard University.